LT2751092T - Selektyvūs ir grįžtami ubikvitiniu specifinės proteazės 7 inhibitoriai - Google Patents

Selektyvūs ir grįžtami ubikvitiniu specifinės proteazės 7 inhibitoriai

Info

Publication number: LT2751092T
Authority: LT; Lithuania
Prior art keywords: selective; specific protease; reversible inhibitors; ubiquitin specific; ubiquitin
Prior art date: 2011-09-02

Application number

LTEP12751080.8T

Other languages

English (en)

Inventor

Frédéric COLLAND

Marie-Edith Gourdel

Original Assignee

Hybrigenics S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-09-02

Filing date

2012-08-29

Publication date

2016-10-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46750347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2751092(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2012-08-29 Application filed by Hybrigenics S.A. filed Critical Hybrigenics S.A.

2016-10-25 Publication of LT2751092T publication Critical patent/LT2751092T/lt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/91—Oxygen atoms with aryl or aralkyl radicals attached in position 2 or 3
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Virology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Oncology (AREA)
Orthopedic Medicine & Surgery (AREA)
Communicable Diseases (AREA)
Immunology (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Obesity (AREA)
Molecular Biology (AREA)
Hematology (AREA)
Cardiology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Biotechnology (AREA)
Psychology (AREA)
Heart & Thoracic Surgery (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

LTEP12751080.8T 2011-09-02 2012-08-29 Selektyvūs ir grįžtami ubikvitiniu specifinės proteazės 7 inhibitoriai LT2751092T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP11306096A EP2565186A1 (en)	2011-09-02	2011-09-02	Selective and reversible inhibitors of ubiquitin specific protease 7
PCT/EP2012/066741 WO2013030218A1 (en)	2011-09-02	2012-08-29	Selective and reversible inhibitors of ubiquitin specific protease 7

Publications (1)

Publication Number	Publication Date
LT2751092T true LT2751092T (lt)	2016-10-25

Family

ID=46750347

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
LTEP12751080.8T LT2751092T (lt)	2011-09-02	2012-08-29	Selektyvūs ir grįžtami ubikvitiniu specifinės proteazės 7 inhibitoriai

Country Status (24)

Country	Link
US (1)	US9546150B2 (lt)
EP (2)	EP2565186A1 (lt)
JP (1)	JP6059228B2 (lt)
KR (1)	KR20140085430A (lt)
CN (1)	CN103930415B (lt)
AR (1)	AR087757A1 (lt)
AU (1)	AU2012300944B2 (lt)
BR (1)	BR112014004649A2 (lt)
CA (1)	CA2847017A1 (lt)
CL (1)	CL2014000511A1 (lt)
DK (1)	DK2751092T3 (lt)
ES (1)	ES2594603T3 (lt)
HU (1)	HUE029418T2 (lt)
IL (1)	IL231203A (lt)
LT (1)	LT2751092T (lt)
MA (1)	MA35361B1 (lt)
MX (1)	MX340500B (lt)
PL (1)	PL2751092T3 (lt)
PT (1)	PT2751092T (lt)
RU (1)	RU2622640C2 (lt)
SG (1)	SG11201400205QA (lt)
SI (1)	SI2751092T1 (lt)
TN (1)	TN2014000079A1 (lt)
WO (1)	WO2013030218A1 (lt)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7
WO2014105952A2 (en)	2012-12-28	2014-07-03	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Inhibitors of the usp1/uaf1 deubiquitinase complex and uses thereof
CN105327350A (zh) *	2014-07-23	2016-02-17	中国科学院上海巴斯德研究所	泛素化途径相关因子在调控辅助性t细胞功能中的应用
TWI698436B (zh) *	2014-12-30	2020-07-11	美商佛瑪治療公司	作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶
MA41291A (fr)	2014-12-30	2017-11-07	Forma Therapeutics Inc	Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer
JP2018504432A (ja)	2015-02-05	2018-02-15	フォーマセラピューティクス，インコーポレイテッド	ユビキチン特異的プロテアーゼ７阻害物質としてのイソチアゾロピリミジノン、ピラゾロピリミジノン及びピロロピリミジノン
WO2016126926A1 (en)	2015-02-05	2016-08-11	Forma Therapeutics, Inc.	Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitors
EP3253765A1 (en) *	2015-02-05	2017-12-13	Forma Therapeutics, Inc.	Thienopyrimidinones as ubiquitin-specific protease 7 inhibitors
CN105251020B (zh) *	2015-09-29	2018-10-09	武汉大学	泛素特异性蛋白酶4（usp4）在治疗心肌肥厚中的功能及应用
GB201522267D0 (en)	2015-12-17	2016-02-03	Mission Therapeutics Ltd	Novel compounds
GB201602854D0 (en) *	2016-02-18	2016-04-06	Mission Therapeutics Ltd	Novel compounds
GB201604638D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
GB201604647D0 (en)	2016-03-18	2016-05-04	Mission Therapeutics Ltd	Novel compounds
FR3061177B1 (fr) *	2016-12-28	2019-09-27	Les Laboratoires Servier	Nouveaux derives piperidinyles hetero(aryle)-substitues, procede pour leur preparation et compositions pharmaceutiques les contenant
RU2742271C2 (ru) *	2016-06-10	2021-02-04	Ле Лаборатуар Сервье	Новые (гетеро)арил-замещенные пиперидинильные производные, способ их получения и фармацевтические композиции, содержащие их
FR3052452B1 (fr)	2016-06-10	2018-06-22	Les Laboratoires Servier	Nouveaux derives de piperidinyle, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR3052451B1 (fr) *	2016-06-10	2018-06-22	Les Laboratoires Servier	Nouveaux derives de piperidinyle hetero(aryl)-substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2018009812A1 (en)	2016-07-08	2018-01-11	Mayo Foundation For Medical Education And Research	Methods and materials for treating cancer
GB201612938D0 (en) *	2016-07-26	2016-09-07	Almac Discovery Ltd	Pharmaceutical compounds
GB201616511D0 (en)	2016-09-29	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201616627D0 (en)	2016-09-30	2016-11-16	Mission Therapeutics Limited	Novel compounds
GB201617758D0 (en) *	2016-10-20	2016-12-07	Almac Discovery Limited	Pharmaceutical compounds
CA3042581A1 (en) *	2016-11-03	2018-05-11	Trillium Therapeutics Inc.	Enhancement of cd47 blockade therapy by proteasome inhibitors
GB201708652D0 (en)	2017-05-31	2017-07-12	Mission Therapeutics Ltd	Novel compounds and uses
JP7208931B2 (ja)	2017-06-20	2023-01-19	ミッションセラピューティクスリミティド	Ｄｕｂ阻害剤としての活性をもつ置換シアノピロリジン類
CA3072353A1 (en) *	2017-09-26	2019-04-04	Dana-Farber Cancer Institute, Inc.	Novel usp7 inhibitors for treating multiple myeloma
GB201801562D0 (en) *	2018-01-31	2018-03-14	Almac Diagnostics Ltd	Pharmaceutical compounds
US12539292B2 (en)	2018-04-01	2026-02-03	Arvinas Operations, Inc.	BRM targeting compounds and associated methods of use
EP3870179A4 (en) *	2018-10-22	2022-11-23	Dana Farber Cancer Institute, Inc.	USP7 ESCAPEMENT
WO2020115501A1 (en) *	2018-12-06	2020-06-11	Almac Discovery Limited	Pharmaceutical compounds and their use as inhibitors of ubiquitin specific protease 19 (usp19)
EP3923987A1 (en)	2019-02-14	2021-12-22	Institut National de la Santé et de la Recherche Médicale (INSERM)	Use of usp7 inhibitors for the treatment of acute myeloid leukemia (aml)
GB201905375D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
GB201905371D0 (en)	2019-04-16	2019-05-29	Mission Therapeutics Ltd	Novel compounds
JP2022540907A (ja) *	2019-07-15	2022-09-20	オンコアレンディセラピューティクスエス．エー．	キチナーゼ阻害剤として有用な置換アミノトリアゾール
GB201912674D0 (en)	2019-09-04	2019-10-16	Mission Therapeutics Ltd	Novel compounds
CN113087718B (zh) *	2020-01-09	2024-02-09	四川科伦博泰生物医药股份有限公司	噻吩并嘧啶酮类化合物及其医药应用
GB202001980D0 (en)	2020-02-13	2020-04-01	Almac Discovery Ltd	Therapeutic mentods
WO2021170290A1 (en) *	2020-02-28	2021-09-02	Immunologik Gmbh	Inhibitors of human deubiquitinases for the treatment of coronaviral infections
US20230119013A1 (en)	2020-04-08	2023-04-20	Mission Therapeutics Limited	N-cyanopyrrolidines with activity as usp30 inhibitors
WO2021242760A1 (en) *	2020-05-26	2021-12-02	Lowell Therapeutics, Inc.	Methods of treating viral infection using protease inhibitors
CA3185027A1 (en)	2020-05-28	2021-12-02	Mission Therapeutics Limited	N-(1-cyano-pyrrolidin-3-yl)-5-(3-(trifluoromethyl)phenyl)oxazole-2-carboxamide derivatives and the corresponding oxadiazole derivatives as usp30 inhibitors for the treatment of mi tochondrial dysfunction
JP7796047B2 (ja)	2020-06-04	2026-01-08	ミッションセラピューティクスリミティド	Ｕｓｐ３０阻害剤としての活性を有するｎ－シアノピロリジン
CN115836073B (zh)	2020-06-08	2024-08-27	特殊治疗有限公司	用于治疗线粒体功能障碍、癌症和纤维化的作为usp30抑制剂的1-(5-(2-氰基吡啶-4-基)噁唑-2-羰基)-4-甲基六氢吡咯并[3,4-b]吡咯-5(1h)-甲腈
CN112047933B (zh) *	2020-10-15	2022-06-14	郑州大学	喹唑啉酮类usp7抑制剂及其制备方法和应用
GB202016800D0 (en)	2020-10-22	2020-12-09	Mission Therapeutics Ltd	Novel compounds
JP2024544660A (ja)	2021-12-01	2024-12-03	ミッションセラピューティクスリミティド	Ｕｓｐ３０阻害剤としての活性を有する置換ｎ－シアノピロリジン
GB202200753D0 (en)	2022-01-21	2022-03-09	Almac Discovery Ltd	Pharmaceutical compounds
GB202408928D0 (en)	2024-06-21	2024-08-07	Mission Therapeutics Ltd	Novel compounds
WO2026015548A1 (en) *	2024-07-08	2026-01-15	Convelo Therapeutics, Inc.	Cyp51 inhibitors and method of using same
GB202411060D0 (en)	2024-07-29	2024-09-11	Mission Therapeutics Ltd	Novel compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2796417A (en) *	1952-04-03	1957-06-18	American Cyanamid Co	Quinazolone compounds and methods of making the same
US3073826A (en) *	1960-10-20	1963-01-15	Mead Johnson & Co	3-pyrrolidylmethyl-4-quinazolones
WO1993012795A1 (en) *	1985-08-30	1993-07-08	Glazer Edward A	Quinazolin-4(3h)-one derivatives as anticoccidial agents
FI95572C (fi)	1987-06-22	1996-02-26	Eisai Co Ltd	Menetelmä lääkeaineena käyttökelpoisen piperidiinijohdannaisten tai sen farmaseuttisen suolan valmistamiseksi
US7842522B2 (en)	2001-10-19	2010-11-30	Applied Nanotech Holdings, Inc.	Well formation
SE0303280D0 (sv)	2003-12-05	2003-12-05	Astrazeneca Ab	Novel compounds
TW200524601A (en) *	2003-12-05	2005-08-01	Bristol Myers Squibb Co	Heterocyclic anti-migraine agents
ES2425476T3 (es) *	2004-04-02	2013-10-15	Prana Biotechnology Limited	Compuestos neurológicamente activos
SE0401656D0 (sv)	2004-06-24	2004-06-24	Astrazeneca Ab	Chemical compounds
WO2006012577A2 (en) *	2004-07-22	2006-02-02	Bayer Pharmaceuticals Corporation	Quinazolinone derivatives useful for the regulation of glucose homeostasis and food intake
NZ553087A (en) *	2004-08-31	2010-12-24	Astrazeneca Ab	Quinazolinone derivatives and their use as B-raf inhibitors
WO2006072048A2 (en)	2004-12-30	2006-07-06	The Trustees Of Princeton University	Compositions and methods for identifying modulators of hausp
US7709516B2 (en)	2005-06-17	2010-05-04	Endorecherche, Inc.	Helix 12 directed non-steroidal antiandrogens
EP1749822B1 (en)	2005-08-05	2008-10-15	Hybrigenics S.A.	Novel cysteine protease inhibitors and their therapeutic applications
EP1924572B1 (en)	2005-09-06	2009-12-30	SmithKline Beecham Corporation	Regioselective process for preparing benzimidazole thiophenes
ES2474865T3 (es) *	2006-06-22	2014-07-09	Prana Biotechnology Limited	Método de tratamiento de un tumor cerebral glioma
US20080188498A1 (en) *	2007-02-05	2008-08-07	Radix Pharmaceuticals, Inc.	Pyridopyrimidinone compounds with antimalarial activity
CN102177152A (zh) *	2008-08-11	2011-09-07	哈佛大学校长及研究员协会	用于抑制tRNA合成酶的卤夫酮(halofuginone)类似物和其用途
WO2010051245A1 (en)	2008-11-03	2010-05-06	Merck Sharp & Dohme Corp.	Benzimidazole and aza-benzimidazole carboxamides
US20110177105A1 (en)	2010-01-15	2011-07-21	Roman Lopez	Novel Selective Inhibitors of Ubiquitin Specific Protease 7, the Pharmaceutical Compositions Thereof and Their Therapeutic Applications
EP2565186A1 (en) *	2011-09-02	2013-03-06	Hybrigenics S.A.	Selective and reversible inhibitors of ubiquitin specific protease 7

2011
- 2011-09-02 EP EP11306096A patent/EP2565186A1/en not_active Withdrawn
2012
- 2012-08-29 DK DK12751080.8T patent/DK2751092T3/en active
- 2012-08-29 RU RU2014112692A patent/RU2622640C2/ru not_active IP Right Cessation
- 2012-08-29 ES ES12751080.8T patent/ES2594603T3/es active Active
- 2012-08-29 AU AU2012300944A patent/AU2012300944B2/en not_active Ceased
- 2012-08-29 PT PT127510808T patent/PT2751092T/pt unknown
- 2012-08-29 WO PCT/EP2012/066741 patent/WO2013030218A1/en not_active Ceased
- 2012-08-29 JP JP2014527641A patent/JP6059228B2/ja not_active Expired - Fee Related
- 2012-08-29 CA CA2847017A patent/CA2847017A1/en not_active Abandoned
- 2012-08-29 PL PL12751080T patent/PL2751092T3/pl unknown
- 2012-08-29 SI SI201230714A patent/SI2751092T1/sl unknown
- 2012-08-29 KR KR1020147007456A patent/KR20140085430A/ko not_active Ceased
- 2012-08-29 HU HUE12751080A patent/HUE029418T2/en unknown
- 2012-08-29 BR BR112014004649A patent/BR112014004649A2/pt not_active Application Discontinuation
- 2012-08-29 MX MX2014002489A patent/MX340500B/es active IP Right Grant
- 2012-08-29 EP EP12751080.8A patent/EP2751092B1/en active Active
- 2012-08-29 SG SG11201400205QA patent/SG11201400205QA/en unknown
- 2012-08-29 CN CN201280054148.2A patent/CN103930415B/zh not_active Expired - Fee Related
- 2012-08-29 LT LTEP12751080.8T patent/LT2751092T/lt unknown
- 2012-08-29 US US14/241,923 patent/US9546150B2/en not_active Expired - Fee Related
- 2012-08-31 AR ARP120103228A patent/AR087757A1/es not_active Application Discontinuation
2014
- 2014-02-21 TN TNP2014000079A patent/TN2014000079A1/en unknown
- 2014-02-25 MA MA36781A patent/MA35361B1/fr unknown
- 2014-02-27 IL IL231203A patent/IL231203A/en active IP Right Grant
- 2014-02-28 CL CL2014000511A patent/CL2014000511A1/es unknown

Also Published As

Publication number	Publication date
PT2751092T (pt)	2016-11-04
US20140371247A1 (en)	2014-12-18
EP2751092B1 (en)	2016-07-27
ES2594603T3 (es)	2016-12-21
MX340500B (es)	2016-07-11
AR087757A1 (es)	2014-04-16
RU2014112692A (ru)	2015-10-10
WO2013030218A4 (en)	2013-04-25
MA35361B1 (fr)	2014-08-01
RU2622640C2 (ru)	2017-06-19
CN103930415A (zh)	2014-07-16
JP2014527064A (ja)	2014-10-09
AU2012300944A1 (en)	2014-03-20
WO2013030218A1 (en)	2013-03-07
NZ621827A (en)	2016-07-29
CN103930415B (zh)	2017-05-24
HUE029418T2 (en)	2017-02-28
IL231203A (en)	2017-04-30
DK2751092T3 (en)	2016-10-10
EP2751092A1 (en)	2014-07-09
SI2751092T1 (sl)	2016-10-28
SG11201400205QA (en)	2014-03-28
IL231203A0 (en)	2014-04-30
JP6059228B2 (ja)	2017-01-11
CA2847017A1 (en)	2013-03-07
BR112014004649A2 (pt)	2017-03-14
KR20140085430A (ko)	2014-07-07
TN2014000079A1 (en)	2015-07-01
MX2014002489A (es)	2014-11-14
CL2014000511A1 (es)	2014-12-05
AU2012300944B2 (en)	2017-06-01
PL2751092T3 (pl)	2017-01-31
US9546150B2 (en)	2017-01-17
EP2565186A1 (en)	2013-03-06

Publication	Publication Date	Title
SG11201400205QA (en)	2014-03-28	Selective and reversible inhibitors of ubiquitin specific protease 7
GB201103526D0 (en)	2011-04-13	Selective glycosidase inhibitors and uses thereof
PL2523938T3 (pl)	2015-02-27	Pochodne aminoakrydyny przydatne jako selektywne inhibitory proteazy 7 specyficznej dla ubikwityny
EP2678018A4 (en)	2015-09-30	COMBINATION OF CHINESE HEMMER AND USES THEREOF
IL230917A0 (en)	2014-03-31	1dyrk inhibitors and uses thereof
EP2663312A4 (en)	2014-10-22	IRAQ INHIBITORS AND THEIR USE
ZA201307499B (en)	2015-09-30	Compositions and methods comprising serine protease variants
HUE047049T2 (hu)	2020-04-28	ACC-gátlók és felhasználásuk
ZA201305531B (en)	2014-10-29	Selective glycosidase inhibitors and uses thereof
HUE053325T2 (hu)	2021-06-28	Plazminogén aktivátor-1 gátlók és ezek alkalmazási eljárásai
ZA201304937B (en)	2014-03-26	Plasminogen and plasmin variants
IL231270A0 (en)	2014-04-30	Inhibitors of monooxygenase - 3 - kynurenine, pharmaceutical compositions, and methods of their use
IL230821A0 (en)	2014-03-31	Variants of plasminogen and plasmin
ZA201307956B (en)	2015-01-28	Pharmaceutical compositions comprising sulbactam and beta-lactamase inhibitor
IL230705A0 (en)	2014-03-31	Certain inhibitors of kynurenine-3-monooxygenase pharmaceutical compositions, and methods of their use
ZA201301795B (en)	2014-05-28	Inhibitors of notum pectinacetylesterase and methods of their use
EP2697246A4 (en)	2015-01-07	CYSTEINE PROTEASE SELECTIVE INHIBITORS AND USES THEREOF
SG11201400102WA (en)	2014-03-28	Inhibitors of nedd8-activating enzyme
SI2655388T1 (sl)	2016-10-28	Selektivni inhibitorji glikozidaze
GB201409877D0 (en)	2014-07-16	Composition pharmaceutical composition of protease inhibitors and production thereof
GB201010084D0 (en)	2010-07-21	Cysteine protease inhibitors
HK1192727A (en)	2014-08-29	Combination of kanase inhibitors and uses thereof
GB201120387D0 (en)	2012-01-11	Cysteine protease inhibitor salt
GB201120378D0 (en)	2012-01-11	Cysteine protease inhibitor salt
AU2011900234A0 (en)	2011-02-10	Serine protease inhibitors